Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 1.4mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 1.6mg

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bosentan monohydrate -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bosentan monohydrate -

Združene države Amerike - angleščina - NLM (National Library of Medicine)

actelion pharmaceuticals us, inc. - mechlorethamine (unii: 50d9xsg0vr) (mechlorethamine - unii:50d9xsg0vr) - mechlorethamine 0.012 g in 60 g - valchlor is an alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin-directed therapy. the use of valchlor is contraindicated in patients with known severe hypersensitivity to mechlorethamine. hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine. pregnancy category d [see warnings and precautions (5.5) ] risk summary mechlorethamine can cause fetal harm when administered to a pregnant woman. there are case reports of children born with malformations in pregnant women systemically administered mechlorethamine. mechlorethamine was teratogenic in animals after a single subcutaneous administration. if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see warnings and precautions (5.5) ]. animal data mechlorethamine caused fetal malformat

Izrael - angleščina - Ministry of Health

j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.

Izrael - angleščina - Ministry of Health

j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 500microgram

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 1.5mg

Izrael - angleščina - Ministry of Health

j-c health care ltd - miglustat - capsules - miglustat 100 mg - miglustat - miglustat - zavesca is indicated for the oral treatment of mild to moderate type i gaucher disease. zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.